Biotech Values

[urche]

Re:Torcetrapib combo, Esperion, and Pfizer

David, Your insights here are much appreciated. I suspect you are exactly right about your assesment that Torcetrapib may end up being a Pyrrhic victory for Pfizer. It may end up approved but unpopular because of the negative sentiment of prescribing physicians being forced to consider a combo drug. It may also end up approved for IVUS results that don't mean much in clinical terms.

I wonder what you think was the motive for Pfizer buying ESPR. It hardly seems a smart business decision to buy a promising company run by admired people and mothball it. I called some unnamed scientist at ESPR just after the purchase was announced to see if the employees shared my euphoria as a small time shareholder. At that time he expected ESPR would continue functioning largely autonomously in a promise exacted from Pfizer. I suspect that man is now deeply disappointed. What do you make of that purchase by Pfizer?

urche